1-7 of 7
William Blum
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories

Clinical Trials & Observations
Uma Borate, Fei Yang, Richard Press, Amy S. Ruppert, Dan Jones, Sean Caruthers, Weiqiang Zhao, Jo-Anne Vergilio, Dean C. Pavlick, Luke Juckett, Brianna Norris, Taylor Bucy, Amy Burd, Eytan M. Stein, Prapti Patel, Maria R. Baer, Wendy Stock, Gary Schiller, William Blum, Tibor Kovacsovics, Mark Litzow, James Foran, Nyla A. Heerema, Leonard Rosenberg, Sonja Marcus, Ashley Yocum, Mona Stefanos, Brian Druker, John C. Byrd, Ross L. Levine, Alice Mims
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6048–6054.
https://doi.org/10.1182/bloodadvances.2022009008
Published: 2023
Includes: Supplemental data
Journal Articles

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1 -mutated AML

Clinical Trials & Observations
Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3117–3127.
https://doi.org/10.1182/bloodadvances.2022009411
Published: 2023
Includes: Supplemental data
Journal Articles

Pevonedistat with azacitidine in older patients with TP53 -mutated AML: a phase 2 study with laboratory correlates

Clinical Trials & Observations
Antoine N. Saliba, Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, Tara L. Lin, Brian J. Ball, Michael M. Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Kevin L. Peterson, Paula A. Schneider, Molly Martycz, Theophilus J. Gana, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Alice S. Mims, Uma Borate, Amy Burd, Brian J. Druker, Ross L. Levine, John C. Byrd, James M. Foran
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2360–2363.
https://doi.org/10.1182/bloodadvances.2022008625
Published: 2023
Includes: Supplemental data
Journal Articles

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Karilyn T. Larkin, Deedra Nicolet, Benjamin J. Kelly, Krzysztof Mrózek, Stephanie LaHaye, Katherine E. Miller, Saranga Wijeratne, Gregory Wheeler, Jessica Kohlschmidt, James S. Blachly, Alice S. Mims, Christopher J. Walker, Christopher C. Oakes, Shelley Orwick, Isaiah Boateng, Jill Buss, Adrienne Heyrosa, Helee Desai, Andrew J. Carroll, William Blum, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Robert J. Mayer, Richard A. Larson, Richard M. Stone, Electra D. Paskett, John C. Byrd, Elaine R. Mardis, Ann-Kathrin Eisfeld
Journal: Blood Advances
Blood Adv (2022) 6 (19): 5570–5581.
https://doi.org/10.1182/bloodadvances.2022007544
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Clinical Trials & Observations
Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2775–2787.
https://doi.org/10.1182/bloodadvances.2021004233
Published: 2021
Includes: Supplemental data
Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Clinical Trials & Observations
Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2020) 4 (4): 696–705.
https://doi.org/10.1182/bloodadvances.2019000492
Published: 2020
Journal Articles

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Clinical Trials & Observations
Jun Yin, Betsy LaPlant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar
Journal: Blood Advances
Blood Adv (2019) 3 (11): 1714–1721.
https://doi.org/10.1182/bloodadvances.2018026112
Published: 2019
Includes: Supplemental data